Analysts’ Viewpoint
Increase in prevalence of genetic disorders, surge in demand for personalized medicine, and expanding applications of genome editing technologies in therapeutic areas are fueling the genome editing market size.
Furthermore, the emergence of CRISPR-Cas9 as a versatile and precise genome editing tool offers lucrative opportunities for market expansion, enabling researchers to edit genes with unprecedented accuracy.
The rise in demand for genome editing tools and services across research institutions, biopharmaceutical companies, and clinical settings is driving market progress. A notable trend is the growth in adoption of CRISPR technology for developing gene therapies and the utilization of genome editing in agriculture for crop improvement.
The genome editing market continues to evolve, indicating a promising future as it addresses critical healthcare needs and contributes to advancements in various scientific domains.
Genome editing is a revolutionary technique that enables precise modification of an organism's DNA, allowing scientists to add, delete, or alter specific genetic elements. Its applications span a wide range of fields, including agriculture, medicine, and biotechnology.
In agriculture, genome editing can be used to create crops with improved traits such as resistance to pests and diseases, increased yield, and enhanced nutritional content.
In medicine, genome editing holds promise to treat genetic disorders by correcting or replacing faulty genes. The CRISPR-Cas9 system, a groundbreaking genome-editing tool, has significantly accelerated research in this area. The technique has undergone continuous refinement, leading to increased accuracy and reduced off-target effects.
Scientists are exploring new editing techniques, such as base editing and prime editing, which offer improved precision and reduced unintended alterations. Ethical considerations involve discussions about the responsible use of genome editing, particularly in the context of human germline editing.
Personalized medicine, an approach that tailors medical treatment to individual characteristics, is gaining immense traction due to its potential to enhance therapeutic outcomes and minimize adverse effects.
As the understanding of the human genome advances, there is an increasing realization that generic treatments may not be optimal for every patient. The demand for personalized medicine arises from the need to address this individual variability in drug response and disease susceptibility.
In the realm of personalized medicine, genome editing holds the promise of developing targeted therapies that can be tailored to the genetic profile of each patient. This approach has the potential to revolutionize the treatment of various genetic disorders, cancers, and other diseases with a genetic component. The ability to edit genes at the molecular level enables the correction of genetic mutations, paving the way for more effective and safer treatment options.
Pharmaceutical companies, biotechnology firms, and research institutions are investing heavily in genome editing technologies to create a new generation of therapies that can be precisely calibrated to the genetic nuances of each patient.
The growth in demand for personalized medicine is a key factor propelling the genome editing market revenue, promising a future where medical treatments are increasingly tailored to the individual, ushering in a new era of precision medicine.
Genetic disorders, often rooted in the individual's DNA, present a significant and rising healthcare challenge globally. The surge in genetic disorders has triggered an unprecedented demand for advanced therapeutic interventions, fostering the genome editing market growth.
As genetic disorders manifest with distinct genetic variations in affected individuals, a one-size-fits-all approach to treatment proves insufficient. Precision allows for tailored therapeutic solutions, aligning with the principles of personalized medicine.
Genome editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, provide precise tools for manipulating the genetic code, allowing scientists and clinicians to modify or correct specific genes associated with diseases.
Additionally, the genome editing market is witnessing a surge in research & development activities aimed at addressing specific genetic anomalies associated with various disorders. The prospect of correcting faulty genes responsible for diseases holds immense promise in the quest for effective treatments and cures.
Consequently, pharmaceutical and biotechnology companies are investing heavily in genome editing technologies to meet the burgeoning demand for personalized therapeutic interventions.
The genome editing market segmentation based on technology includes Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-like Effector Nuclease (TALEN), Zinc Finger Nuclease (ZFN), and other technologies.
Simplicity, versatility, and cost-effectiveness have enabled CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to emerge as the frontrunner in the genome editing market.
CRISPR offers a more user-friendly approach, enabling a broader scientific community to adopt and implement genome editing techniques. CRISPR allows researchers to quickly adapt and target different genes by simply redesigning the guide RNA. This adaptability accelerates the pace of research & development in various fields, from agriculture to medicine.
Ethical concerns surrounding gene editing, the potential for off-target effects, and regulatory uncertainties are likely to restrain the market. Additionally, the high cost associated with genome editing technologies poses a barrier to widespread adoption. The COVID-19 pandemic further impacted the market, disrupting supply chains and diverting resources toward pandemic-related research.
The evolving landscape of genome editing promises transformative impacts on agriculture, medicine, and beyond, but careful consideration and responsible implementation are essential as the technology continues to advance.
As per the latest genome editing market forecast, North America currently holds a dominant position that reflects its advanced technological infrastructure, well-established healthcare system, and robust research & development activities.
A strong emphasis on biotechnological advancements, significant investments in genomic research, and a high prevalence of genetic disorders further drive market dynamics in the region. The presence of major market players, academic institutions, and biotech firms dedicated to genome editing technologies also propels North America's dominance.
Asia Pacific is an expanding market for genome editing technologies. Surge in awareness and adoption of personalized medicine in the region and a rising population and growth in focus on precision healthcare is leading to heightened demand for advanced genomic tools and therapies. A large pool of skilled researchers and scientists foster innovation and advancements in genome editing in the region.
The genome editing market report provides profiles of leading players. Merck KGaA, AstraZeneca, Takara Bio Inc., Cellectis SA, CRISPR Therapeutics., Cibus Inc., RECOMBINETICS, Sangamo Therapeutics, and Thermo Fisher Scientific, Inc. are the key entities operating in this market.
These players engage in mergers & acquisitions, strategic collaborations, and new product launches to expand their presence and gain substantial market share.
Key companies have been profiled in the report based on various factors including company overview, financial summary, strategies, product portfolio, segments, and recent advancements.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 5.5 Bn |
| Market Forecast (Value) in 2031 | More than US$ 17.5 Bn |
| Growth Rate (CAGR) 2023-2031 | 13.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 5.5 Bn in 2022
It is projected to reach more than US$ 17.5 Bn by the end of 2031
The CAGR is anticipated to be 13.9% from 2023 to 2031
Based on technology, the CRISPR segment accounted for largest share in 2022
North America is anticipated to account for leading share during the forecast period.
Merck KGaA, AstraZeneca, Takara Bio Inc., Cellectis SA, CRISPR Therapeutics., Cibus Inc., RECOMBINETICS, Sangamo Therapeutics, and Thermo Fisher Scientific, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Genome Editing Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Genome Editing Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario
5.2. Technological Advancements
5.3. Covid-19 Pandemic Impact on Industry
6. Global Genome Editing Market Analysis and Forecasts, By Technology
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Technology, 2017-2031
6.3.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
6.3.2. Transcription activator-like effector nuclease (TALEN)
6.3.3. Zinc finger nuclease (ZFN)
6.3.4. Other technologies
6.4. Market Attractiveness By Technology
7. Global Genome Editing Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2017-2031
7.3.1. Cell Line Editing
7.3.2. Animal Genome Editing
7.3.3. Plant Genome Editing
7.3.4. Others
7.4. Market Attractiveness By Application
8. Global Genome Editing Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2017-2031
8.3.1. Pharmaceutical Companies and Biotechnology Companies
8.3.2. Academics and Government Research Institutes
8.3.3. Clinical Research Organizations
8.4. Market Attractiveness By End-user
9. Global Genome Editing Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Genome Editing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Technology, 2017-2031
10.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
10.2.2. Transcription activator-like effector nuclease (TALEN)
10.2.3. Zinc finger nuclease (ZFN)
10.2.4. Other technologies
10.3. Market Value Forecast By Application, 2017-2031
10.3.1. Cell Line Editing
10.3.2. Animal Genome Editing
10.3.3. Plant Genome Editing
10.3.4. Others
10.4. Market Value Forecast By End-user, 2017-2031
10.4.1. Pharmaceutical Companies and Biotechnology Companies
10.4.2. Academics and Government Research Institutes
10.4.3. Clinical Research Organizations
10.5. Market Value Forecast By Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Technology
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Genome Editing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Technology, 2017-2031
11.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
11.2.2. Transcription activator-like effector nuclease (TALEN)
11.2.3. Zinc finger nuclease (ZFN)
11.2.4. Other technologies
11.3. Market Value Forecast By Application, 2017-2031
11.3.1. Cell Line Editing
11.3.2. Animal Genome Editing
11.3.3. Plant Genome Editing
11.3.4. Others
11.4. Market Value Forecast By End-user, 2017-2031
11.4.1. Pharmaceutical Companies and Biotechnology Companies
11.4.2. Academics and Government Research Institutes
11.4.3. Clinical Research Organizations
11.5. Market Value Forecast By Country, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Technology
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country
12. Asia Pacific Genome Editing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Technology, 2017-2031
12.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
12.2.2. Transcription activator-like effector nuclease (TALEN)
12.2.3. Zinc finger nuclease (ZFN)
12.2.4. Other technologies
12.3. Market Value Forecast By Application, 2017-2031
12.3.1. Cell Line Editing
12.3.2. Animal Genome Editing
12.3.3. Plant Genome Editing
12.3.4. Others
12.4. Market Value Forecast By End-user, 2017-2031
12.4.1. Pharmaceutical Companies and Biotechnology Companies
12.4.2. Academics and Government Research Institutes
12.4.3. Clinical Research Organizations
12.5. Market Value Forecast By Country, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Technology
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country
13. Latin America Genome Editing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Technology, 2017-2031
13.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
13.2.2. Transcription activator-like effector nuclease (TALEN)
13.2.3. Zinc finger nuclease (ZFN)
13.2.4. Other technologies
13.3. Market Value Forecast By Application, 2017-2031
13.3.1. Cell Line Editing
13.3.2. Animal Genome Editing
13.3.3. Plant Genome Editing
13.3.4. Others
13.4. Market Value Forecast By End-user, 2017-2031
13.4.1. Pharmaceutical Companies and Biotechnology Companies
13.4.2. Academics and Government Research Institutes
13.4.3. Clinical Research Organizations
13.5. Market Value Forecast By Country, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Technology
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country
14. Middle East & Africa Genome Editing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Technology, 2017-2031
14.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
14.2.2. Transcription activator-like effector nuclease (TALEN)
14.2.3. Zinc finger nuclease (ZFN)
14.2.4. Other technologies
14.3. Market Value Forecast By Application, 2017-2031
14.3.1. Cell Line Editing
14.3.2. Animal Genome Editing
14.3.3. Plant Genome Editing
14.3.4. Others
14.4. Market Value Forecast By End-user, 2017-2031
14.4.1. Pharmaceutical Companies and Biotechnology Companies
14.4.2. Academics and Government Research Institutes
14.4.3. Clinical Research Organizations
14.5. Market Value Forecast By Country, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Technology
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Merck KGaA
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Takara Bio Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Cellectis SA
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. CRISPR Therapeutics
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Cibus Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. RECOMBINETICS
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Sangamo Therapeutics
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Thermo Fisher Scientific, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 02: Global Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 03: Global Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 04: Global Genome Editing Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Genome Editing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 07: North America Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 08: North America Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 09: Europe Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 11: Europe Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 12: Europe Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 13: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 16: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 17: Latin America Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 19: Latin America Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 20: Latin America Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 23: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 24: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Genome Editing Market Size, by Technology, 2022
Figure 02: Global Genome Editing Market Share (%), by Technology, 2022
Figure 03: Global Genome Editing Market Size, by Application, 2022
Figure 04: Global Genome Editing Market Share (%), by Application, 2022
Figure 05: Global Genome Editing Market Size, by End-user, 2022
Figure 06: Global Genome Editing Market Share (%), by End-user, 2022
Figure 07: Global Genome Editing Market, by Region (2022-2031)
Figure 08: Global Genome Editing Market Value (US$ Mn) Forecast, 2017-2031
Figure 09: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031
Figure 10: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022
Figure 11: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2031
Figure 12: Global Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031
Figure 13: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031
Figure 14: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022
Figure 15: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2031
Figure 16: Global Genome Editing Market Attractiveness Analysis, by Application, 2023-2031
Figure 17: Global Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031
Figure 18: Global Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022
Figure 19: Global Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2031
Figure 20: Global Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 21: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Region, 2022-2031
Figure 22: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Region, 2022
Figure 23: Global Genome Editing Market Value (US$ Mn) Share Analysis, by Region, 2031
Figure 24: Global Genome Editing Market Attractiveness Analysis, by Region, 2023-2031
Figure 25: North America Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 26: North America Genome Editing Market Value Share Analysis, by Country, 2022-2031
Figure 27: North America Genome Editing Market Attractiveness Analysis, by Country, 2023-2031
Figure 28: North America Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031
Figure 29: North America Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031
Figure 30: North America Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031
Figure 31: North America Genome Editing Market Attractiveness Analysis, by Application, 2023-31
Figure 32: North America Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031
Figure 33: North America Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 34: Europe Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 35: Europe Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 36: Europe Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 37: Europe Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031
Figure 38: Europe Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031
Figure 39: Europe Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031
Figure 40: Europe Genome Editing Market Attractiveness Analysis, by Application, 2023-2031
Figure 41: Europe Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031
Figure 42: Europe Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 43: Asia Pacific Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 44: Asia Pacific Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 45: Asia Pacific Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 46: Asia Pacific Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031
Figure 47: Asia Pacific Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031
Figure 48: Asia Pacific Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031
Figure 49: Asia Pacific Genome Editing Market Attractiveness Analysis, by Application, 2023-2031
Figure 50: Asia Pacific Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031
Figure 51: Asia Pacific Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 52: Latin America Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 53: Latin America Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 54: Latin America Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 55: Latin America Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031
Figure 56: Latin America Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031
Figure 57: Latin America Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031
Figure 58: Latin America Genome Editing Market Attractiveness Analysis, by Application, 2023-2031
Figure 59: Latin America Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031
Figure 60: Latin America Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 61: Middle East & Africa Genome Editing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 62: Middle East & Africa Genome Editing Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 63: Middle East & Africa Genome Editing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 64: Middle East & Africa Genome Editing Market Value (US$ Mn) Share Analysis, by Technology, 2022-2031
Figure 65: Middle East & Africa Genome Editing Market Attractiveness Analysis, by Technology, 2023-2031
Figure 66: Middle East & Africa Genome Editing Market Value (US$ Mn) Share Analysis, by Application, 2022-2031
Figure 67: Middle East & Africa Genome Editing Market Attractiveness Analysis, by Application, 2023-2031
Figure 68: Middle East & Africa Genome Editing Market Value (US$ Mn) Share Analysis, by End-user, 2022-2031
Figure 69: Middle East & Africa Genome Editing Market Attractiveness Analysis, by End-user, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Genome Editing Market
*86 figures and 60 tables includes